Previous analyses of FANCD2 and BRIP1/BACH1 in non-BRCA1/2 families failed to identify any pathogenic mutations [14,16,17]; however, these studies did not choose the families to be screened on the basis of haplotype sharing, or the occurrence of other cancers (e.g. ovarian cancer in the case of FANCD2) in the family. This evidence concerns the gene BRIP1 and ovarian carcinoma.